文献速递系统性红斑狼疮

系统性红斑狼疮常用免疫抑制剂感染住院风险比较:目标试验模拟研究

Comparative Safety of Common Immunosuppressant Therapies in Systemic Lupus Erythematosus: A Target Trial Emulation Study.
PubMed 文献 · Arthritis Rheumatol · 2026-09-17

该研究采用目标试验模拟方法,基于Optum Labs数据对非肾性系统性红斑狼疮患者启动硫唑嘌呤、贝利尤单抗、甲氨蝶呤或霉酚酸类似物后的感染相关住院风险进行比较,发现24个月累积发生率霉酚酸类似物最高(13%),贝利尤单抗最低(8%)。ITT和PP分析中霉酚酸类似物/硫唑嘌呤风险高于贝利尤单抗,但调整时间变化糖皮质激素剂量后差异不再显著。

要点

  • 霉酚酸类似物24个月感染住院累积发生率13%,贝利尤单抗最低为8%。
  • ITT分析中霉酚酸类似物感染住院风险高于贝利尤单抗(HR 1.55)和甲氨蝶呤(HR 1.32)。
  • 调整时间变化糖皮质激素剂量后,治疗间感染住院风险差异不再显著。

核心结论

  • 初始观察到的感染相关住院风险差异在考虑时间变化的糖皮质激素暴露后减弱。
  • 糖皮质激素暴露是与严重感染风险相关的重要因素,但基线后激素使用可能反映疾病活动变化及治疗影响感染风险的途径。

研究设计与样本

  • 采用Optum Labs数据仓库索赔数据模拟目标试验,纳入2011年3月至2023年9月启动硫唑嘌呤、贝利尤单抗、甲氨蝶呤或霉酚酸类似物的非肾性系统性红斑狼疮患者。
  • 排除既往狼疮肾炎、实体器官或骨髓移植、或利妥昔单抗/环磷酰胺暴露者。
  • 主要结局为首次感染相关住院时间,采用意向性治疗(ITT)和符合方案(PP)分析,应用逆概率治疗加权调整基线协变量,并拟合边际结构Cox模型纳入随访期间每月时间变化糖皮质激素剂量。

主要发现

  • 共纳入6,168例患者,24个月感染相关住院累积发生率:硫唑嘌呤10%(95%CI 8-12)、贝利尤单抗8%(95%CI 5-10)、甲氨蝶呤10%(95%CI 8-11)、霉酚酸类似物13%(95%CI 10-15)。
  • ITT分析中,霉酚酸类似物感染住院风险高于贝利尤单抗(HR 1.55,95%CI 1.07-2.25)和甲氨蝶呤(HR 1.32,95%CI 1.04-1.68)。
  • PP分析中,硫唑嘌呤(HR 2.04,95%CI 1.01-4.16)和霉酚酸类似物(HR 2.27,95%CI 1.11-4.62)感染住院风险高于贝利尤单抗。
  • 考虑时间变化每月糖皮质激素剂量后,治疗间差异不再显著。

关键数值与推荐

  • 24个月感染相关住院累积发生率:硫唑嘌呤10%(95%CI 8-12)、贝利尤单抗8%(95%CI 5-10)、甲氨蝶呤10%(95%CI 8-11)、霉酚酸类似物13%(95%CI 10-15)。
  • ITT分析HR:霉酚酸类似物 vs 贝利尤单抗1.55(95%CI 1.07-2.25);霉酚酸类似物 vs 甲氨蝶呤1.32(95%CI 1.04-1.68)。
  • PP分析HR:硫唑嘌呤 vs 贝利尤单抗2.04(95%CI 1.01-4.16);霉酚酸类似物 vs 贝利尤单抗2.27(95%CI 1.11-4.62)。

临床怎么用

  • 对于非肾性系统性红斑狼疮患者,选择免疫抑制剂时应考虑感染住院风险,贝利尤单抗在未调整激素剂量时显示较低风险。
  • 糖皮质激素暴露是严重感染风险的重要相关因素,临床应关注激素剂量的管理。

局限性

  • 基线后糖皮质激素使用可能反映疾病活动变化,也可能是治疗影响感染风险的途径,解释治疗间差异时需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to compare infection-related hospitalization risk among patients with nonrenal systemic lupus erythematosus initiating commonly used immunosuppressants. METHODS: We emulated a target trial using Optum Labs Data Warehouse claims to compare the risk of infection-related hospitalization among patients initiating azathioprine, belimumab, methotrexate, or mycophenolic acid analogues (MPAAs) between March 2011 and September 2023. We excluded patients with prior lupus nephritis, solid-organ or bone marrow transplantation, or rituximab/cyclophosphamide exposure. The primary outcome was time to first infection-related hospitalization using intention-to-treat (ITT) and per-protocol (PP) analyses. We applied inverse probability of treatment weighting to account for baseline covariates and fitted marginal structural Cox models incorporating time-varying monthly glucocorticoid dose during follow-up. RESULTS: Among 6,168 patients, 24-month cumulative incidence of infection-related hospitalization was 10% (95% confidence interval [CI] 8-12) for azathioprine, 8% (95% CI 5-10) for belimumab, 10% (95% CI 8-11) for methotrexate, and 13% (95% CI 10-15) for MPAAs. In ITT analyses, MPAAs had higher risk than belimumab (hazard ratio [HR] 1.55, 95% CI 1.07-2.25) and methotrexate (HR 1.32, 95% CI 1.04-1.68). In PP analyses, azathioprine (HR 2.04, 95% CI 1.01-4.16) and MPAAs (HR 2.27, 95% CI 1.11-4.62) had higher risk compared with belimumab. After accounting for time-varying monthly glucocorticoid dose, between-treatment differences were no longer significant. CONCLUSION: Initial differences in the infection-related hospitalization risk were attenuated after accounting for time-varying glucocorticoid exposure. These findings highlight glucocorticoid exposure as an important factor associated with serious infection risk while recognizing that postbaseline glucocorticoid use may reflect both evolving disease activity and a pathway through which therapies influence infection risk.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Duarte-García A, Sandino-Bermúdez MJ, González-Treviño M, et al. Comparative Safety of Common Immunosuppressant Therapies in Systemic Lupus Erythematosus: A Target Trial Emulation Study. Arthritis Rheumatol. 2026. PMID: 42750573. doi:10.1002/art.70343

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。